

Status: Currently Official on 13-Feb-2025
Official Date: Official as of 01-Dec-2023
Document Type: USP Monographs
DocId: GUID-72521BA4-4162-45A5-A4E6-7DD3D80AC2FC_4_en-US
DOI: https://doi.org/10.31003/USPNF_M205_04_01
DOI Ref: re3vl

© 2025 USPC
Do not distribute

Acetaminophen Extended-Release Tablets

To view the Notice from the Expert Committee that posted in conjunction with this accelerated revision, please click www.uspnf.com/rb-acetaminophen-ert-20231117.

DEFINITION

Acetaminophen Extended-Release Tablets contain NLT 90.0% and NMT 110.0% of the labeled amount of acetaminophen ($C_8H_9NO_2$).

IDENTIFICATION

- **A. SPECTROSCOPIC IDENTIFICATION TESTS (197), Infrared Spectroscopy:** 197K

Sample: A portion of powdered Tablets

Acceptance criteria: Meet the requirements

- **B.** The retention time of the *Sample solution* corresponds to that of the *Standard solution*, as obtained in the Assay.

ASSAY

PROCEDURE

Solution A: [Phosphoric acid](#) and [water](#) (1:9)

Mobile phase: [Methanol](#), *Solution A*, and [water](#) (300:1:700)

Standard solution: 0.65 mg/mL of [USP Acetaminophen RS](#) in *Mobile phase*. Prepare by first dissolving in [methanol](#), and then diluting with *Mobile phase* to volume.

Sample stock solution: Transfer 10 Tablets to a 250-mL volumetric flask containing 50 mL of [water](#) and a magnetic stir bar. Stir for at least 30 min or until the coating has dissolved. Add 150 mL of [methanol](#), and stir for 45 min. Tablet cores should be disintegrated at least 15 min before ending the stirring. Remove the magnetic stir bar, and rinse into the flask with [methanol](#). Dilute with [methanol](#) to volume, and centrifuge. Use the clear supernatant.

Sample solution: Dilute 5 mL of the *Sample stock solution* with *Mobile phase* to 200 mL.

Chromatographic system

(See [Chromatography \(621\), System Suitability](#).)

Mode: LC

Detector: UV 295 nm

Column: 3.9-mm × 15-cm; packing [L1](#)

Flow rate: 2.0 mL/min

Injection volume: 20 µL

System suitability

Sample: *Standard solution*

Suitability requirements

Tailing factor: NMT 3.0

Relative standard deviation: NMT 2.0%

Analysis

Samples: *Standard solution* and *Sample solution*

Calculate the percentage of the labeled amount of acetaminophen ($C_8H_9NO_2$) in the portion of Tablets taken:

$$\text{Result} = (r_U/r_S) \times (C_S/C_U) \times 100$$

r_U = peak response from the *Sample solution*

r_S = peak response from the *Standard solution*

C_S = concentration of [USP Acetaminophen RS](#) in the *Standard solution* (mg/mL)

C_U = nominal concentration of acetaminophen in the *Sample solution* (mg/mL)

Acceptance criteria: 90.0%–110.0%

PERFORMANCE TESTS

Change to read:

• [DISSOLUTION \(711\)](#)**Test 1****Medium:** [Simulated gastric fluid TS](#) (without enzyme); 900 mL**Apparatus 2:** 50 rpm**Times:** 15 min, 1 h, and 3 h**Standard solution:** A known concentration of [USP Acetaminophen RS](#) in *Medium***Sample solution:** A filtered portion of the solution under test, suitably diluted with *Medium* to obtain a concentration similar to that of the *Standard solution***Instrumental conditions****Mode:** UV**Analytical wavelength:** 280 nm**Analysis****Samples:** *Standard solution* and *Sample solution*Calculate the percentage of the labeled amount of acetaminophen ($C_8H_9NO_2$) dissolved.**Tolerances:** See [Table 1](#).**Table 1**

Time	Amount Dissolved
15 min	45%–65%
1 h	60%–85%
3 h	NLT 85%

The percentages of the labeled amount of acetaminophen ($C_8H_9NO_2$) dissolved at the times specified conform to [Acceptance Table 2](#) in [\(711\)](#).

For gelatin-coated Tablets**Medium, Apparatus, Standard solution, Sample solution, Instrumental conditions, and Analysis:** Proceed as directed in *Test 1*.**Times:** 30 min, 90 min, and 4 h**Tolerances:** See [Table 2](#).**Table 2**

Time	Amount Dissolved
30 min	40%–60%
90 min	55%–85%
4 h	NLT 80%

The percentages of the labeled amount of acetaminophen ($C_8H_9NO_2$) dissolved at the times specified conform to [Acceptance Table 2](#) in [\(711\)](#).

Test 2: If the product complies with this test, the labeling indicates that it meets USP *Dissolution Test 2*.**Medium, Apparatus, Standard solution, Sample solution, Instrumental conditions, and Analysis:** Proceed as directed in *Test 1*.**Times:** 15 min, 1 h, and 3 h**Tolerances:** See [Table 3](#).**Table 3**

Time	Amount Dissolved
15 min	40%–60%
1 h	55%–75%
3 h	NLT 80%

The percentages of the labeled amount of acetaminophen ($C_8H_9NO_2$) dissolved at the times specified conform to [Acceptance Table 2](#) in [\(711\)](#).

Test 3: If the product complies with this test, the labeling indicates that it meets USP *Dissolution Test 3*.

Medium: [Simulated gastric fluid TS](#) (without enzyme); 900 mL

Apparatus 2: 50 rpm

Times: 30, 90, and 240 min

Standard stock solution: 1.44 mg/mL of [USP Acetaminophen RS](#) in [methanol](#). Sonicate to dissolve, if necessary.

Standard solution: ($L/9000$) mg/mL of [USP Acetaminophen RS](#) from *Standard stock solution* in *Medium*, where L is the label claim in mg/Tablet

Sample solution: At the times specified, withdraw 10 mL of the solution under test and replace with 10 mL of *Medium*. Pass the solution under test through a suitable filter of 0.45- μ m pore size. Dilute with *Medium* to a concentration that is similar to that of the *Standard solution*.

Instrumental conditions

Mode: UV

Analytical wavelength: 280 nm

Analysis

Samples: *Standard solution* and *Sample solution*

Calculate the concentration (C_i) of acetaminophen ($C_8H_9NO_2$) in the sample withdrawn from the vessel at each time point (i):

$$\text{Result}_i = (A_U/A_S) \times C_S \times D$$

A_U = absorbance of the *Sample solution*

A_S = absorbance of the *Standard solution*

C_S = concentration of [USP Acetaminophen RS](#) in the *Standard solution* (mg/mL)

D = dilution factor for the *Sample solution*

Calculate the percentage of the labeled amount of acetaminophen ($C_8H_9NO_2$) dissolved at each time point (i):

$$\text{Result}_1 = C_1 \times V \times (1/L) \times 100$$

$$\text{Result}_2 = [(C_2 \times V) + (C_1 \times V_S)] \times (1/L) \times 100$$

$$\text{Result}_3 = \{(C_3 \times V) + [(C_2 + C_1) \times V_S]\} \times (1/L) \times 100$$

C_i = concentration of acetaminophen in the portion of sample withdrawn at time point i (mg/mL)

V = volume of *Medium*, 900 mL

L = label claim (mg/Tablet)

V_S = volume of the *Sample solution* withdrawn at each time point and replaced with *Medium* (mL)

Tolerances: See [Table 4](#).

Table 4

Time Point (i)	Time (min)	Amount Dissolved (%)
1	30	45–65
2	90	65–85
3	240	NLT 85

The percentages of the labeled amount of acetaminophen ($C_8H_9NO_2$) dissolved at the times specified conform to [Dissolution \(711\)](#), [Acceptance Table 2](#).

▲ **Test 4:** If the product complies with this test, the labeling indicates that it meets USP *Dissolution Test 4*.

Medium: [Gastric fluid, simulated TS](#) (without enzyme); deaerated, 900 mL

Apparatus 2: 50 rpm

Times: 15, 60, and 180 min

Mobile phase: [Methanol](#), [glacial acetic acid](#), and [water](#) (20:1:79)

Standard solution: 0.72 mg/mL of [USP Acetaminophen RS](#) prepared as follows. Transfer an appropriate quantity of [USP Acetaminophen RS](#) to a suitable volumetric flask, add 2% of the flask volume of [methanol](#), and if necessary, sonicate to dissolve. Dilute with *Medium* to volume.

Sample solution: At the times specified, pass a portion of the solution under test through a suitable filter, discarding an appropriate volume of filtrate so that a consistent result can be obtained.

Chromatographic system

(See [Chromatography \(621\)](#), [System Suitability](#).)

Mode: LC

Detector: UV 280 nm

Column: 4.6-mm × 7.5-cm; 3.5-μm packing [L7](#)

Flow rate: 1.5 mL/min

Injection volume: 5 μL

Run time: NLT 1.7 times of the retention time of acetaminophen

System suitability

Sample: *Standard solution*

Suitability requirements

Tailing factor: NMT 2.5

Relative standard deviation: NMT 2.0%

Analysis

Samples: *Standard solution and Sample solution*

Calculate the concentration (C_i) of acetaminophen ($C_8H_9NO_2$) in the sample withdrawn from the vessel at each time point (i):

$$\text{Result}_i = (r_U/r_S) \times C_S$$

r_U = peak response of acetaminophen from the *Sample solution*

r_S = peak response of acetaminophen from the *Standard solution*

C_S = concentration of [USP Acetaminophen RS](#) in the *Standard solution* (mg/mL)

Calculate the percentage of the labeled amount of acetaminophen ($C_8H_9NO_2$) dissolved at each time point (i):

$$\text{Result}_1 = C_1 \times V \times (1/L) \times 100$$

$$\text{Result}_2 = \{[C_2 \times (V - V_S)] + (C_1 \times V_S)\} \times (1/L) \times 100$$

$$\text{Result}_3 = \{[C_3 \times [V - (2 \times V_S)]] + [(C_2 + C_1) \times V_S]\} \times (1/L) \times 100$$

C_i = concentration of acetaminophen in the portion of sample withdrawn at time point i (mg/mL)

V = volume of *Medium*, 900 mL

L = label claim (mg/Tablet)

V_S = volume of the *Sample solution* withdrawn at each time point from the *Medium* (mL)

Tolerances: See [Table 5](#).

Table 5

Time Point (i)	Time (min)	Amount Dissolved (%)
1	15	45–65
2	60	60–80
3	180	NLT 80

The percentages of the labeled amount of acetaminophen ($C_8H_9NO_2$) dissolved at the times specified conform to [Dissolution \(711\)](#), [Acceptance Table 2](#). ▲ (RB 1-Dec-2023)

- [UNIFORMITY OF DOSAGE UNITS \(905\)](#): Meet the requirements

IMPURITIES

- [4-AMINOPHENOL IN ACETAMINOPHEN-CONTAINING DRUG PRODUCTS \(227\)](#): Meet the requirements

ADDITIONAL REQUIREMENTS

- **PACKAGING AND STORAGE:** Preserve in tight containers.

- **LABELING:** Where the Tablets are gelatin-coated, the label so states. When more than one *Dissolution* test is given, the labeling states the *Dissolution* test used only if *Test 1* is not used.
- **USP REFERENCE STANDARDS (11),**
[USP Acetaminophen RS](#)

Auxiliary Information - Please [check for your question in the FAQs](#) before contacting USP.

Topic/Question	Contact	Expert Committee
ACETAMINOPHEN EXTENDED-RELEASE TABLETS	Documentary Standards Support	SM22020 Small Molecules 2

Chromatographic Database Information: [Chromatographic Database](#)

Most Recently Appeared In:

Pharmacopeial Forum: Volume No. PF 39(3)

Current DocID: GUID-72521BA4-4162-45A5-A4E6-7DD3D80AC2FC_4_en-US

DOI: https://doi.org/10.31003/USPNF_M205_04_01

DOI ref: [re3v1](#)

OFFICIAL